

# HORMONAL IUDs AVAILABLE IN AUSTRALIA COMPARISON CHART FOR PRESCRIBERS AND IUD INSERTERS

## REFERENCES:

1. Contraception for Users Over 40 Years: Information for Health Practitioners 2020 [cited 2020 16 October]. Available from: <https://www.fpv.org.au/resource/contraception-for-users-over-40-years-health-practitioner-faqs>.
2. Gemzell-Danielsson K, Apter D, Dermout S, Faustmann T, Rosen K, Schmelter T, et al. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use. *Eur J Obstet Gynecol Reprod Biol.* 2017;210:22-8.
3. Heinemann K, Reed S, Moehner S, Minh TD. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. *Contraception.* 2015;91(4):280-3.
4. Apter D, Gemzell-Danielsson K, Hauck B, Rosen K, Zurth C. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. *Fertility and sterility.* 2014;101(6):1656-62 e1-4.
5. Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. *Fertility and sterility.* 2012;97(3):616-22 e1-3.
6. Goldthwaite LM, Creinin MD. Comparing bleeding patterns for the levonorgestrel 52 mg, 19.5 mg, and 13.5 mg intrauterine systems. *Contraception.* 2019;100(2):128-31.
7. Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT. Levonorgestrel-Releasing Intrauterine System or Medroxyprogesterone for Heavy Menstrual Bleeding: A Randomized Controlled Trial. *Obstet Gynecol.* 2010;116(3):625-32.
8. Kelekci S, Kelekci KH, Yilmaz B. Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis. *Contraception.* 2012;86(5):458-63.
9. Lindh I, Milsom I. The influence of intrauterine contraception on the prevalence and severity of dysmenorrhea: a longitudinal population study. *Hum Reprod.* 2013;28(7):1953-60.
10. Nilsson CG, Luukkainen T, Diaz J, Allonen H. Clinical performance of a new levonorgestrel-releasing intrauterine device. A randomized comparison with a nova-T-copper device. *Contraception.* 1982;25(4):345-56.
11. Abou-Setta AM, Al-Inany HG, Farquhar CM. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. *Cochrane database of systematic reviews.* 2006(4):CD005072.
12. Gomes MK, Ferriani RA, Rosa e Silva JC, Japur de Sa Rosa e Silva AC, Vieira CS, Candido dos Reis FJ. The levonorgestrel-releasing intrauterine system and endometriosis staging. *Fertility and sterility.* 2007;87(5):1231-4.
13. Pontis A, D'Alterio MN, Pirarba S, de Angelis C, Tinelli R, Angioni S. Adenomyosis: a systematic review of medical treatment. *Gynecol Endocrinol.* 2016;32(9):696-700.
14. FSRH Guideline. Drug Interactions with Hormonal Contraception: Faculty of Sexual & Reproductive Healthcare Statement. Clinical Effectiveness Unit; 2017 [cited 2019 30 August]. January 2019:[Available from: <https://www.fsrh.org/standards-and-guidance/documents/ceu-clinical-guidance-drug-interactions-with-hormonal/>].

